Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cg Oncology Inc (CGON)

Cg Oncology Inc (CGON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CG Oncology Announces New Board Member and Board Transition GlobeNewswire - Wed Nov 26, 6:00AM CST

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

CGON : 44.73 (+4.98%)
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting GlobeNewswire - Tue Nov 25, 3:05PM CST

IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...

CGON : 44.73 (+4.98%)
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Fri Nov 14, 7:00AM CST

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Demonstrated...

CGON : 44.73 (+4.98%)
Analysts Offer Insights on NA Companies: Rubrik, Inc. Class A (RBRK) and CG Oncology, Inc. (CGON) Tipranks - Fri Oct 3, 7:10AM CDT

There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Rubrik, Inc. Class A (RBRK – Research Report) and CG Oncology, Inc. (CGON – Research Report) with bullish sentiments.Elevate...

CGON : 44.73 (+4.98%)
RBRK : 70.43 (-1.37%)
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market Newswire.ca - Mon Sep 8, 8:30AM CDT

/CNW/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...

ONCY : 0.9807 (+8.19%)
IDYA : 36.01 (+4.86%)
HCM : 14.16 (-0.70%)
CGON : 44.73 (+4.98%)
CCCC : 2.59 (-7.83%)
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire - Mon Sep 8, 8:30AM CDT

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc.

ONCY : 0.9807 (+8.19%)
IDYA : 36.01 (+4.86%)
HCM : 14.16 (-0.70%)
CGON : 44.73 (+4.98%)
CCCC : 2.59 (-7.83%)
CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences GlobeNewswire - Fri Aug 29, 7:00AM CDT

IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...

CGON : 44.73 (+4.98%)
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Fri Aug 8, 7:00AM CDT

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - ...

CGON : 44.73 (+4.98%)
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals GlobeNewswire - Tue Jul 29, 3:05PM CDT

IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...

ANIP : 82.74 (+0.08%)
CGON : 44.73 (+4.98%)
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs FinancialNewsMedia - Mon Jul 7, 7:30AM CDT

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END

CLDI : 1.5400 (+2.67%)
MRK : 100.89 (-1.35%)
VRTX : 457.36 (-1.25%)
REGN : 722.80 (-0.12%)
RHHBY : 48.2000 (-1.47%)
CGON : 44.73 (+4.98%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot